1887
Volume 2004, Issue 1
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

The benefits of cholesterol-lowering with statins has been established for patients with high cholesterol levels as well as for patients with prior occlusive coronary heart disease. However; substantial uncertainty has existed about the long-term benefits of these agents in certain groups, including patients with “normal” cholesterol levels pretreatment, women, the elderly, as well as those with prior occlusive non-coronary disease. The Heart Protection Study 1 was designed to resolve these uncertainties and to provide substantially more safety information of statins. We present its significance and practical implications.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2004.1.6
2004-06-01
2020-02-19
Loading full text...

Full text loading...

References

  1. Heart Protection Collaborative Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 individuals: A randomised placebo-controlled trial. Lancet. 2002; 360::722.
    [Google Scholar]
  2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344::13831389.
    [Google Scholar]
  3. Shepherd J, Cobbe SM, Ford I, et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333::13011307.
    [Google Scholar]
  4. Sacks FM, Pfejfer MA, Moye LA, et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335::10011009.
    [Google Scholar]
  5. Downs JR, Clearfield M, Weis S, et al., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279::16151622.
    [Google Scholar]
  6. The Long-Term Intervention With Pravastatin In Ischemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339::13491357.
    [Google Scholar]
  7. Salam AM. Expanding indications of statins; implications of the Heart Protection Study. Expert Opin Investig Drugs. 2003; 12::509513.
    [Google Scholar]
  8.   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final report. Circulation. 2002; 106:25:31433421.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2004.1.6
Loading
  • Article Type: Review Article
Keyword(s): and tutorials , cholesterol , Coronary disease , lipid lowering and statins
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error